Jianjun Zhang

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Supplementary Figure S3 from Mechanisms of Response and Tolerance to Active RAS Inhibition in <i>KRAS</i>-Mutant Non–Small Cell Lung Cancer

  2026-06-17

• Supplementary Figure S5 from Mechanisms of Response and Tolerance to Active RAS Inhibition in <i>KRAS</i>-Mutant Non–Small Cell Lung Cancer

  2026-06-17

• Supplementary Figure S13 from Mechanisms of Response and Tolerance to Active RAS Inhibition in <i>KRAS</i>-Mutant Non–Small Cell Lung Cancer

  2026-06-17

• Supplementary Figure S7 from Mechanisms of Response and Tolerance to Active RAS Inhibition in <i>KRAS</i>-Mutant Non–Small Cell Lung Cancer

  2026-06-17

• Supplementary Figure S2 from Mechanisms of Response and Tolerance to Active RAS Inhibition in <i>KRAS</i>-Mutant Non–Small Cell Lung Cancer

  2026-06-17

• Supplementary Figure S6 from Mechanisms of Response and Tolerance to Active RAS Inhibition in <i>KRAS</i>-Mutant Non–Small Cell Lung Cancer

  2026-06-17

• Supplementary Figure S11 from Mechanisms of Response and Tolerance to Active RAS Inhibition in <i>KRAS</i>-Mutant Non–Small Cell Lung Cancer

  2026-06-17

• Supplementary Figure S9 from Mechanisms of Response and Tolerance to Active RAS Inhibition in <i>KRAS</i>-Mutant Non–Small Cell Lung Cancer

  2026-06-17

• Supplementary Figure S4 from Mechanisms of Response and Tolerance to Active RAS Inhibition in <i>KRAS</i>-Mutant Non–Small Cell Lung Cancer

  2026-06-17

• Supplementary Figure S12 from Mechanisms of Response and Tolerance to Active RAS Inhibition in <i>KRAS</i>-Mutant Non–Small Cell Lung Cancer

  2026-06-17

• Supplementary Figure S10 from Mechanisms of Response and Tolerance to Active RAS Inhibition in <i>KRAS</i>-Mutant Non–Small Cell Lung Cancer

  2026-06-17

• Supplementary Figure S1 from Mechanisms of Response and Tolerance to Active RAS Inhibition in <i>KRAS</i>-Mutant Non–Small Cell Lung Cancer

  2026-06-17

• Supplementary Figure S15 from Mechanisms of Response and Tolerance to Active RAS Inhibition in <i>KRAS</i>-Mutant Non–Small Cell Lung Cancer

  2026-06-17

• Supplementary Figure S14 from Mechanisms of Response and Tolerance to Active RAS Inhibition in <i>KRAS</i>-Mutant Non–Small Cell Lung Cancer

  2026-06-17

• Supplementary Figure S8 from Mechanisms of Response and Tolerance to Active RAS Inhibition in <i>KRAS</i>-Mutant Non–Small Cell Lung Cancer

  2026-06-17

• Deciphering small sequence differences in T cell receptor-antigen pairing

  Nature Communications · 2026-06-13

• CT-Based Deep Foundation Model for Predicting Immune Checkpoint Inhibitor-Induced Pneumonitis Risk in Lung Cancer

  medRxiv · 2026-04-23

• Financial toxicity and its association with quality of life and psychological distress among patients with gynecologic cancers receiving radiotherapy in China: a multicenter cross-sectional study

  Frontiers in Public Health · 2026-04-13

• Interferon regulatory factors: the next prospective targets for tissue ischemia–reperfusion injury?

  Frontiers in Immunology · 2026-04-07

• Abstract 7316: Targeting sulfatide metabolism as a therapeutic vulnerability in pancreatic pre-cancer lesions

  Cancer Research · 2026-04-03